XENON PHARMACEUTICALS INC. Deferred Revenue
XENON PHARMACEUTICALS INC. (XENE) had Deferred Revenue of $157.00 thousand as of 2015-12-31, per its 10-K filed 2017-03-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2017-03-08
- 2015-12-31: Deferred Revenue, Current $157.00K.
- 2015-09-30: Deferred Revenue, Current $2.51M.
- 2015-06-30: Deferred Revenue, Current $5.63M.
- 2015-03-31: Deferred Revenue, Current $8.72M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2015-12-31 | $157.00K 10-K · filed 2017-03-08 |
| 2015-09-30 | $2.51M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $5.63M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $8.72M 10-Q/A · filed 2015-08-13 |
| 2014-12-31 | $11.62M 10-K · filed 2016-03-08 |
| 2014-09-30 | $13.52M 10-Q · filed 2014-12-15 |
| 2013-12-31 | $15.92M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |